Carna Biosciences (TSE:4572) Shares Outstanding (EOP): 19.1 Mil (As of Dec. 2025)


TSE:4572 Carna Biosciences Inc TSE:4572
24 GF Score
Price 円337.00
GF Value 円174.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Carna Biosciences Shares Outstanding (EOP)?

Carna Biosciences TSE:4572 -0.59% 24 Shares Outstanding (EOP) is 19.1 Mil as of Dec. 2025. GuruFocus rates TSE:4572 with a GF Score™ of 24/100 and a GF Value™ of 円174.75 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Carna Biosciences's shares outstanding for the quarter that ended in Dec. 2025 was 19.1 Mil.

Carna Biosciences's quarterly shares outstanding increased from Jun. 2025 (19.1 Mil) to Dec. 2025 (19.1 Mil). It means Carna Biosciences issued new shares from Jun. 2025 to Dec. 2025 .

Carna Biosciences's annual shares outstanding increased from Dec. 2024 (19.1 Mil) to Dec. 2025 (19.1 Mil). It means Carna Biosciences issued new shares from Dec. 2024 to Dec. 2025 .


Carna Biosciences  (TSE:4572) Shares Outstanding (EOP) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Carna Biosciences Shares Outstanding (EOP) Related Terms


Carna Biosciences Shares Outstanding (EOP) Historical Data

* Premium members only.

The historical data trend for Carna Biosciences's Shares Outstanding (EOP) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Carna Biosciences Shares Outstanding (EOP) Chart

Carna Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shares Outstanding (EOP)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.31 14.21 17.15 19.10 19.14

Carna Biosciences Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Dec25 Mar26
Shares Outstanding (EOP) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 19.10 19.10 19.10 19.14 19.19

TSE:4572 vs VRTX, REGN, ALNY: Shares Outstanding (EOP) Comparison

For the Biotechnology subindustry, Carna Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Carna Biosciences Shares Outstanding (EOP) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Carna Biosciences's Shares Outstanding (EOP) distribution charts can be found below:

* The bar in red indicates where Carna Biosciences's Shares Outstanding (EOP) falls into.


TSE:4572
24GF Score
Carna Biosciences Inc TSE:4572
Shares Outstanding (EOP) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Carna Biosciences Shares Outstanding (EOP) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (EOP) of 19.1 Mil mean?
Carna Biosciences (TSE:4572) has a Shares Outstanding (EOP) of 19.1 Mil as of Dec. 2025. The total shares a company has outstanding, at period-end. View historical data on Carna Biosciences and its competitors.
Is Carna Biosciences' Shares Outstanding (EOP) too high?
Carna Biosciences' current Shares Outstanding (EOP) is 19.1 Mil. Overall, Carna Biosciences has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Carna Biosciences' Shares Outstanding (EOP) compare to VRTX and REGN?
Carna Biosciences' Shares Outstanding (EOP) of 19.1 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (EOP) for a Biotechnology company?
A good Shares Outstanding (EOP) depends on the Biotechnology industry context. However, Shares Outstanding (EOP) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (EOP) mean?
A high Shares Outstanding (EOP) can signal that a stock is expensive relative to its fundamentals. The total shares a company has outstanding, at period-end. View historical data on Carna Biosciences and its competitors. Carna Biosciences's current Shares Outstanding (EOP) is 19.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Carna Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Carna Biosciences (TSE:4572) is currently considered Significantly Overvalued. The stock's GF Value™ is 円174.75, compared to a current price of 円337.00 — trading 92.8% above its estimated fair value. The current Shares Outstanding (EOP) is 19.1 Mil. Carna Biosciences' overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (EOP) calculated?
Shares Outstanding (EOP) is calculated from a company's financial statements. For Carna Biosciences (TSE:4572), the current Shares Outstanding (EOP) is 19.1 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Carna Biosciences (TSE:4572) Overvalued in 2026?

Based on GuruFocus' analysis, Carna Biosciences stock appears to be overvalued. The current stock price of 円337.00 is trading 92.8% above its estimated GF Value™ of 円174.75. GuruFocus considers Carna Biosciences to be Significantly Overvalued.

Key valuation signals for TSE:4572:

  • Shares Outstanding (EOP): 19.1 Mil
  • GF Value™: 円174.75 vs. price of 円337.00 (92.8% above fair value)
  • GF Score™: 24/100 with 6 warning signs

No single metric tells the full story. See the TSE:4572 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Carna Biosciences Business Description

Address BMA 3F 1-5-5 Minatojima-Minamimachi, Kobe, JPN, 650-0047
Carna Biosciences Inc is a Japanese company engaged in drug discovery support business and drug discovery and development business. The company identifies and develops medicines for the treatment of cancer and inflammatory diseases using own kinase drug discovery platform, QuickScout.
24GF Score

Get the complete analysis for TSE:4572

Shares Outstanding (EOP) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円337.00
Price
円174.75
GF Value